Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31158105 | 0.80 | BLM (0.33) | TSHR | |
| SCHEMBL13166778 | 0.79 | KMT2A (0.32) | — | |
| SCHEMBL12428896 | 0.78 | PIK3CD (0.41) | — | |
| SCHEMBL16016797 | 0.78 | CA12 (0.32) | TSHR | |
| SCHEMBL24337239 | 0.78 | BLM (0.34) | — | |
| SCHEMBL10085154 | 0.77 | ACHE (0.33) | — | |
| SCHEMBL2736349 | 0.76 | PIK3CD (0.37) | — | |
| SCHEMBL13992418 | 0.76 | — | — | |
| SCHEMBL16016803 | 0.74 | CA12 (0.36) | — | |
| SCHEMBL7940771 | 0.74 | PIK3CD (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009139922-A2 | PEPTOID COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7462592-B2 | Compositions and methods for polynucleotide delivery | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | ZUCKERMANN RONALD N | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089938-A9 | Compositions and methods for polynucleotide delivery | POLN, RNASE1, NCL | TSHR 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.